Skip to main content

A glimpse of the ERM proteins


In all eukaryotes, the plasma membrane is critically important as it maintains the architectural integrity of the cell. Proper anchorage and interaction between the plasma membrane and the cytoskeleton is critical for normal cellular processes. The ERM (ezrin-radixin-moesin) proteins are a class of highly homologous proteins involved in linking the plasma membrane to the cortical actin cytoskeleton. This review takes a succinct look at the biology of the ERM proteins including their structure and function. Current reports on their regulation that leads to activation and deactivation was examined before taking a look at the different interacting partners. Finally, emerging roles of each of the ERM family members in cancer was highlighted.


The ERM proteins are evolutionary conserved group of three related proteins (ezrin, radixin and moesin) that possess band Four point one (4.1) as a common origin [1]. They interact with the plasma membrane through a common FERM (Four point one, ERM) domain [2]. The ERM proteins are located in cellular structures such as filopodia, lamellipodia, apical microvilli, ruffling membranes, cleavage furrow of mitotic cells, retraction fibres, and adhesion sites, where the plasma membrane interacts with F-actin [3]. ERMs are critical for structural stability and for maintaining the integrity of the cell cortex by coupling transmembrane proteins to the actin cytoskeleton [1]. These proteins also play very pivotal intracellular scaffolding roles that aid signal transduction between the intracellular and extracellular compartments of the cell as well as interacting with other membrane phospholipids [4]. Thus, ERMs are involved in regulating several cellular processes including reorganization of actin cytoskeleton, cell survival, membrane dynamics, cell migration, adhesion and regulation of membrane protrusion [4, 5].


Structure of ERM proteins

Structurally, at the amino terminus of ERM proteins is an approximately 1-296 amino acid FERM domain also known as N-terminal ERM association domain (N-ERMAD) through which they interact with cell membranes. X-ray crystallography revealed that the FERM domain consists of F1, F2 and F3, also respectively referred to as A, B and C subdomains that fold and joined together to form an cloverleaf structure, and these subdomains are homologous to ubiquitin, acyl-CoA binding protein and plekstrin homology domains respectively [4, 5] (Fig. 1). The FERM region is closely flanked by a central (approximately 200 amino acid) α–helical domain that form coiled coils [4] and mediate interaction with protein kinase A (PKA) [6]. The carboxylic terminal tail consists of 107 residues, and this terminus contains the F-actin binding site through which ERMs interact with the actin cytoskeleton [7]. In all ERM family members, distinct domains within the N-terminal head and C-terminal tail known as N- and C-ezrin-radixin-moesin association domains (N-ERMAD and C-ERMAD respectively) mediates homotypic and heterotypic head-to-tail interaction [4, 8, 9]. The N-ERMAD is distinct from the C-ERMAD in that it is a labile domain that is inactivated by chemical agents such as sodium dodecyl sulfate (SDS) treatment, and its activity is negatively affected by freeze thawing, whereas the C-ERMAD is unaffected by chemical treatment [10].

Fig. 1

Basic Structure of ERM Proteins. All ERM proteins possess similar domain structure with the N terminus having F1, F2 and F3 subdomains. At the central portion of the protein is an α-helical domain which is followed by a linker region. At the last 30 carboxyl terminal end is the F-actin binding site

ERMs exist in a dormant, inactive closed conformation within the cytosol in which the C-ERMAD stretches from the F-actin binding site through F2 and F3 to part of the FERM region, thereby concealing both the F-actin and the membrane binding sites from other binding partners [7, 10, 11]. This covering of FERM by the C-ERMAD is bolstered by the central α-helical domain in that it binds the FERM domain to facilitate masking of both domains [4]. Activation of ERMs requires opening up the binding sites in the FERM domain and those of the F-actin biding sites in the C-terminal domain. This is achieved by phosphatidylinositol 4,5-bisphosphate (PIP2)-mediated uncoupling of the C-terminal domain from the FERM domain [1].

Regulation of ERM proteins

ERM proteins function is regulated by a two-step process of open (active) and closed (inactive) conformation [12]. They are mainly regulated through conformational changes induced by phospholipids and kinases-mediated phosphorylation, and this results in activation of the proteins [13]. Recruitment of ERMs to areas of the plasma membrane containing high amount of phosphoinositides such as PIP2 exposes a conserved regulatory threonine phosphorylation residue (T567, T564 and T558 in ezrin, radixin and moesin respectively) located in the C-ERMAD domain [14], and this induces a successive activation mechanism whereby PIP2 first bind to a subdomain in the N-terminal FERM domain followed by plasma membrane translocation and phosphorylation of the threonine residues [15]. There are three lysine-rich consensus sites known to bind phosphoinositides on the FERM domain of ERM proteins and mutation on any of these sites inhibited PIP2-ERM interaction and translocation to the plasma membrane [16]. PIP2-mediated recruitment of ERMs to the plasma membrane is sufficient not only in the phosphorylation of these proteins by other kinases, but also in the formation of microvilli [17].

Phosphorylation of the conserved threonine residue can be induced by different signaling protein kinases such as Rho-associated protein kinase (ROCK), myotonic dystrophy kinase-related Cdc42-binding kinase, G-protein coupled receptor kinase 2, Nck interacting kinase [14, 1820], protein kinase C (PKCα, PKCβ), NFкB-inducing kinase (NIK), lymphocyte-oriented kinase (LOK) thereby creating stearic hindrance that keeps the FERM and C-ERMAD domains apart [11, 2123], and this stabilizes the active state of ERM proteins in their open conformation [15, 17]. Ezrin can be phosphorylated by cyclic-dependent kinase 5 (CDK5) on threonine 235 which lies between the FERM and C-ERMAD domains, and mutation of this site facilitated ezrin localization to plasma membrane [24].

Binding of ERM proteins to the cytoskeleton in many cases is strengthened by phosphorylation of the proteins [25]. Activation of the small Rho GTPase, RhoA and not Rac or Cdc42 was able to induce phosphorylation of both radixin and moesin, and this paralleled formation of membrane protrusions in Swiss 3 T3 cells [26]. Also upon activation of platelets with thrombin, the phosphorylation status of moesin on threonine 558 (a residue also phosphorylated by PKCθ) was enhanced and this bolstered the interaction of moesin with the cytoskeleton, and moesin was found localized at the spreading filopodia [27]. Phosphorylation of radixin on threonine 564 at the C-terminal half by Rho-kinase had no effect on the C-ERMAD to bind F-actin, but attenuated the ability of the C-ERMAD to bind N-ERMAD [28] suggesting that the activated state of ERM proteins during which the intramolecular interaction between the N- and C- terminal domains is inhibited, can be sustained by the phosphorylation of threonine 564 in radixin [25], threonines 558 and 567 in moesin and ezrin respectively [29].

ERM proteins can also be phosphorylated by receptor tyrosine kinases. Epidermal growth factor (EGF) receptor can phosphorylate ezrin at tyrosines 145 and 353 (Y145 and Y353) [30]. In epithelial kidney cells, Y353 phosphorylation is required for not only binding of phosphatidylinositol 3-kinase to ezrin, but for the activation of Akt signaling pathway [31]. Similarly, stimulation of ezrin-transfected LLC-PK1 cells with hepatocyte growth factor (HGF) resulted in increased phosphorylation of ezrin at the same tyrosine residues and this not only promoted cell migration, but also enhanced intracellular signal transduction [32]. Ezrin Y145 phosphorylation was demonstrated in Jurkat T-cells expressing Lck (a Src family kinase), but not in Lck-deficient cells [33].

It is now known that ERM proteins are also activated by sphingolipids. For instance in several cell lines such as A549, HEK, MEF, MCF7 and MDA cells, expression of the bioactive sphingolipid, sphingosine-1-phosphate (S1P) both endogenously and exogenously resulted in phosphorylation and activation of ezrin in a time- and dose-dependent manner [34, 35], and in Hela cells, S1P-mediated phosphorylation was found to be through S1P receptor 2 (S1PR2). This was required for filopodia formation [34]. In a PKC-dependent manner, S1P stimulation of pulmonary endothelial cells resulted in activation of ezrin and moesin, but not radixin [36, 37]. However, contrary to its known functions, via unclear mechanisms, S1P phosphorylation of ezrin resulted in inhibition of cell invasion, and this could be attributed to the ability of S1P to act on different receptors [35]. In Hela cells, generation of plasma membrane ceramide through breakdown of sphingomyelin by the action of sphingomyelinase resulted in dephosphorylation of ERM proteins, while decreasing plasma membrane levels of the sphingolipid resulted in ERM proteins hyperphosphorylation [12].

Regulation of ERM proteins is also brought about by dephosphorylation and inactivation of the proteins through the activities of phosphatases, and via PIP2 hydrolysis. In Hela cells, ceramide drives ERM dephosphorylation through activation of protein phosphatase 1α (PP1α) with the resultant effect of inactivating ERM and subsequent dissociation from the plasma membrane [38]. Similarly, overexpression of the small protein tyrosine phosphatase, phosphatase of regenerating liver-3 (PRL-3) in HCT116 colon cancer cell line resulted in dephosphorylation of ezrin [39]. Moesin can be downregulated by myosin light chain phosphatase through dephosphorylation of threonine 558 [40]. Although, in phorbol 12-myristate 13 acetate (PMA)-stimulated leucocytes, ezrin is inactivated through calpain-mediated cleavage, moesin and radixin are insensitive to cleavage by calpain [41] suggesting that distinct regulatory mechanisms exist for each protein in the same cell.

Interaction of ERMs with other proteins

There are several proteins within the plasma membrane that interact with activated ERM proteins through the FERM domain. In a manner dependent on PIP2, ERM proteins can associate with the cytoplasmic tails of intracellular adhesion molecules -1, -3 (ICAM-1 and -3) [42] and -2 (ICAM-2), as well as the hyaluronan receptor CD44 and CD43 [43]. ERMs are also known to bind PDZ (postsynaptic density protein)-containing proteins such as transporters and ion channels through other anchoring proteins like NHERF1 (Na+-H+ exchanger regulatory factor) also known as ERM-binding phosphoprotein 50 (EBP50) and NHERF2 [44, 45]. They also interact with membrane glycoproteins such as P-selectin glycoprotein ligand-1 which tether white blood cells to injured tissues [42]. The α-helical domain on the central portion of ERMs can also bind subunits of HOPS complex (homotypic fusion and protein sorting) as well as the regulatory subunits RII of protein kinase A [46]. Binding of ERM proteins to PKA tethers it to downstream targets to effect cAMP-mediated biological processes such as cell differentiation, proliferation, metabolism, apoptosis, exocytosis, T cell and B cell activation, muscle contraction [6]. In COS-1 cells, ezrin was shown to bind and link syndecan-2 to the cortical cytoskeleton [47]. The death receptor Fas/CD95, unlike other membrane proteins that bind all ERM proteins, did not bind to moesin but only to ezrin in T lymphocytes [48].

ERM proteins and cancer

Cancer cell migration is a coordinated process involving different steps that bring about loss of cell-cell adhesion and deregulation of cell-matrix interaction. Several reports have outlined different factors such as localization of ERMs within the cell, their level of phosphorylation as well as expression profile to be responsible for ERM proteins-mediated promotion of tumourigenesis [2]. Below is a brief discussion of each of the ERM proteins, with the aim of highlighting their significance in different human cancers.


Abnormal localization of ERM proteins is a leading factor resulting aberrant intracellular signal transduction triggered by growth factors. For instance, in breast carcinoma, ezrin which was originally situated at apical structures in normal cell was found translocated to the cytoplasm and plasma membrane and this aberrant localization resulted in the acquisition of an epithelial-mesenchymal transition (EMT) in which cells loss their normal differentiated, planar and apical-based polarity and anchorage dependent architecture and instead acquire metastatic phenotype that correlated with poor prognosis [49].

In epithelial cells, interaction of ezrin with Fes kinase causes recruitment and activation of the later at the cell membrane where it facilitates HGF-mediated loss of cell-cell and cell-ECM contacts resulting in cell migration as revealed by wound healing assay [32, 50]. In this interaction, ezrin not only localized to the leading edge of migrating epithelial cells [50], but also promoted the formation of membrane protrusions [2].

Similarly, upon phosphorylation of the ERM proteins by PKCα, ERMs can act as downstream effector of PKC to mediate cell migration when the later was stimulated with phorbol-ester [51]. PKC activation by phorbol ester also caused a switch in phosphorylation site of the transmembrane receptor CD44 from Ser325 to Ser29 and this phosphorylation regulated the association of ezrin with CD44 to promote directional cell migration triggered by CD44 [52]. Ezrin binds cell-neural adhesion molecule (L1-CAM) to promote progression of colorectal cancer in that RNA interference of ezrin activity inhibited tumour metastasis mediated by L1-CAM [53]. In 3D matrigel matrix, perturbation of ezrin activity with small hairpin RNA technology reduced the metastatic and invasive capabilities of MDA-MB-231 and MCF10A breast cancer cell lines [54]. Ezrin Y145 phosphorylation in mouse mammary carcinoma cell line SP1 [55] and in pig kidney epithelial LLC-PK1 [56] cells resulted in cell spreading. Elevated expression of ezrin has been reported in LTE, BE1, H446 and H460 lung cancer cell lines, and a substantial decrease in migration, proliferation and invasion was observed upon siRNA-mediated knockdown of ezrin [57]. In high grade prostate cancers, overexpression of ezrin has been reported [58, 59], and this was attributed to increased expression of oncogenic c-Myc [60]. Interestingly, ezrin itself, through a feedback loop involving the Akt/PI3K pathway can regulate c-Myc levels and this is crucial for cell migration and invasion [60, 61]. Ezrin overexpression has been shown in other cancer such as pancreatic carcinoma, rhabdomyosarcoma and osteosarcoma [6264].


Although, much is not known about the role of radixin in cancer, unlike ezrin, however, radixin has been implicated in prostate cancer progression [65]; and impairment of radixin in human pancreatic cancer cell line by shRNA not only significantly attenuated cell proliferation, survival, adhesion and invasion but also enhanced expression levels of the cell-cell adhesion molecule, E-cadherin [66]. In a manner dependent on Vav (a guanine exchange nucleotide factor for Rac1) activity, downregulation of radixin levels resulted in an increase in Rac1 activity [67]. In radixin, phosphorylation of a conserved threonine 564 residue is sufficient to prevent the interaction of the FERM domain at the N-terminus with the F-actin binding domain at the C-ERMAD terminus, and this results in constitutive opening of the membrane and F-actin binding domains [68]. Indeed, in Madin-Darby canine kidney (MDCK) epithelial cells, phosphorylation of radixin on this site (T564) by the G protein-coupled receptor kinase 2 (GRK2) was able to induce membrane protrusions as well as increased migration of the cells as determined by wound healing assay [69]. In contrast to the aforementioned positive roles of radixin in tumourigenesis, a novel role in which the protein appeared to inhibit metastasis has been reported. According to this report, perturbation of radixin activity in the metastatic prostate cancer cell line PC3 by siRNA technology resulted in an elevated increase in spreading of cells, enhanced cell-cell adhesion and acquisition of epithelial phenotype [70].


Expression of moesin has been correlated with increased tumour size and invasive capability, and there was an aberrant trafficking of the protein from plasma membrane to the cytosol in oral squamous carcinoma cell (OSCC) in which moesin was knocked down [71]. Similarly, whereas high grade glioblastoma showed high expression levels of moesin, there was no change in expression levels of ezrin and radixin [72]. Moesin promoted tumour cell invasion in that in vitro 3D cell migration assays revealed that moesin depleted-cells exhibited reduced invasiveness [61, 73]. Moesin is considered an important promoter of metastasis as it has been shown to induce EMT in human mammary cell MCF10A [74], and there are now emerging reports that moesin is upregulated in different human cancer cell lines [75, 76] as well as a marker of EMT [74, 77, 78]. In the same vein, high level of moesin was also found in head and neck squamous cell carcinoma [79]. Whereas both moesin and radixin were found upregulated in lymph node metastases of pancreatic cancer, the level of ezrin expression was unaffected, but its phosphorylation status did change [80].

Conclusion and future perspectives

ERM proteins play very vital role in maintaining cellular integrity and in mediating signal transduction from different extracellular inputs through their interaction different receptor tyrosine kinases (RTKs) such as EGFR and HGFR, adhesion and adaptor proteins such as E-cadherin, ICAM-1,2,3, NHERF and CD44, and other signaling pathways such as PI3K/Akt, cAMP/PKA and the Rho GTPases, all of which have been implicated in tumorigenesis; thus, making ERM proteins important target in development of novel therapeutics in fighting cancer progression. Although, there are ample reports on involvement of ERMs in cancer, detailed understanding of the mechanisms of their interactions with other proteins as well as their activation is still lacking and requires further investigation.



Epidermal growth factor


Epithelial-mesenchymal transition


Ezrin, radixin, moesin


Four point one ERM domain


Hepatocyte growth factor


Intracellular adhesion molecule


Lymphocyte oriented kinase


Na+-H+ exchanger regulatory factor

PIP2 :

Phosphatidylinositol 4,5-bisphosphate


Protein kinase A/C


Receptor tyrosine kinases




  1. 1.

    Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol. 2010;11(4):276–87.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Arpin M, Chirivino D, Naba A, Zwaenepoel I. Emerging role for ERM proteins in cell adhesion and migration. Cell Adhes Migr. 2011;5(2):199–206.

    Article  Google Scholar 

  3. 3.

    Wakayama T, Nakata H, Kurobo M, Sai Y, Iseki S. Expression, localization, and binding activity of the ezrin/radixin/moesin proteins in the mouse testis. J Histochem Cytochem. 2009;57(4):351–62.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Pore D, Gupta N. The ezrin-radixin-moesin family of proteins in the regulation of B-cell immune response. Crit Rev Immunol. 2015;35(1):15–31.

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3(8):586–99.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Dransfield DT, Bradford AJ, Smith J, Martin M, Roy C, Mangeat PH, Goldenring JR. Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J. 1997;16(1):35–43.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Hamada K, Shimizu T, Yonemura S, Tsukita S, Hakoshima T. Structural basis of adhesion-molecule recognition by ERM proteins revealed by the crystal structure of the radixin-ICAM-2 complex. EMBO J. 2003;22(3):502–14.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Algrain M, Turunen O, Vaheri A, Louvard D, Arpin M. Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. J Cell Biol. 1993;120(1):129–39.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Pore D, Bodo J, Danda A, Yan D, Phillips JG, Lindner D, Hill BT, Smith MR, Hsi ED, Gupta N. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma. Leukemia. 2015;29(9):1857–67.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Gary R, Bretscher A. Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol Biol Cell. 1995;6(8):1061–75.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Pearson MA, Reczek D, Bretscher A, Karplus PA. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell. 2000;101(3):259–70.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Canals D, Jenkins RW, Roddy P, Hernandez-Corbacho MJ, Obeid LM, Hannun YA. Differential effects of ceramide and sphingosine 1-phosphate on ERM phosphorylation: probing sphingolipid signaling at the outer plasma membrane. J Biol Chem. 2010;285(42):32476–85.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Bonilha VL. Focus on molecules: ezrin. Exp Eye Res. 2007;84(4):613–4.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Nakamura N, Oshiro N, Fukata Y, Amano M, Fukata M, Kuroda S, Matsuura Y, Leung T, Lim L, Kaibuchi K. Phosphorylation of ERM proteins at filopodia induced by Cdc42. Genes Cells. 2000;5(7):571–81.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Fievet BT, Gautreau A, Roy C, Del Maestro L, Mangeat P, Louvard D, Arpin M. Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin. J Cell Biol. 2004;164(5):653–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Barret C, Roy C, Montcourrier P, Mangeat P, Niggli V. Mutagenesis of the phosphatidylinositol 4,5-bisphosphate (PIP(2)) binding site in the NH(2)-terminal domain of ezrin correlates with its altered cellular distribution. J Cell Biol. 2000;151(5):1067–80.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Yonemura S, Matsui T, Tsukita S. Rho-dependent and -independent activation mechanisms of ezrin/radixin/moesin proteins: an essential role for polyphosphoinositides in vivo. J Cell Sci. 2002;115(Pt 12):2569–80.

    CAS  PubMed  Google Scholar 

  18. 18.

    Baumgartner M, Sillman AL, Blackwood EM, Srivastava J, Madson N, Schilling JW, Wright JH, Barber DL. The Nck-interacting kinase phosphorylates ERM proteins for formation of lamellipodium by growth factors. Proc Natl Acad Sci U S A. 2006;103(36):13391–6.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Cant SH, Pitcher JA. G protein-coupled receptor kinase 2-mediated phosphorylation of ezrin is required for G protein-coupled receptor-dependent reorganization of the actin cytoskeleton. Mol Biol Cell. 2005;16(7):3088–99.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Oshiro N, Fukata Y, Kaibuchi K. Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J Biol Chem. 1998;273(52):34663–6.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Nakamura F, Huang L, Pestonjamasp K, Luna EJ, Furthmayr H. Regulation of F-actin binding to platelet moesin in vitro by both phosphorylation of threonine 558 and polyphosphatidylinositides. Mol Biol Cell. 1999;10(8):2669–85.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Belkina NV, Liu Y, Hao JJ, Karasuyama H, Shaw S. LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation. Proc Natl Acad Sci U S A. 2009;106(12):4707–12.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Pietromonaco SF, Simons PC, Altman A, Elias L. Protein kinase C-theta phosphorylation of moesin in the actin-binding sequence. J Biol Chem. 1998;273(13):7594–603.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Yang HS, Hinds PW. Increased ezrin expression and activation by CDK5 coincident with acquisition of the senescent phenotype. Mol Cell. 2003;11(5):1163–76.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol. 1999;11(1):109–16.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Shaw RJ, Henry M, Solomon F, Jacks T. RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. Mol Biol Cell. 1998;9(2):403–19.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Nakamura F, Amieva MR, Furthmayr H. Phosphorylation of threonine 558 in the carboxyl-terminal actin-binding domain of moesin by thrombin activation of human platelets. J Biol Chem. 1995;270(52):31377–85.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol. 1998;140(3):647–57.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Ivetic A, Ridley AJ. Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes. Immunology. 2004;112(2):165–76.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Krieg J, Hunter T. Identification of the two major epidermal growth factor-induced tyrosine phosphorylation sites in the microvillar core protein ezrin. J Biol Chem. 1992;267(27):19258–65.

    CAS  PubMed  Google Scholar 

  31. 31.

    Gautreau A, Poullet P, Louvard D, Arpin M. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1999;96(13):7300–5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Crepaldi T, Gautreau A, Comoglio PM, Louvard D, Arpin M. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol. 1997;138(2):423–34.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Autero M, Heiska L, Ronnstrand L, Vaheri A, Gahmberg CG, Carpen O. Ezrin is a substrate for Lck in T cells. FEBS Lett. 2003;535(1-3):82–6.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Gandy KA, Canals D, Adada M, Wada M, Roddy P, Snider AJ, Hannun YA, Obeid LM. Sphingosine 1-phosphate induces filopodia formation through S1PR2 activation of ERM proteins. Biochem J. 2013;449(3):661–72.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Adada M, Canals D, Hannun YA, Obeid LM. Sphingolipid regulation of ezrin, radixin, and moesin proteins family: implications for cell dynamics. Biochim Biophys Acta. 2014;1841(5):727–37.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Adyshev DM, Moldobaeva NK, Elangovan VR, Garcia JG, Dudek SM. Differential involvement of ezrin/radixin/moesin proteins in sphingosine 1-phosphate-induced human pulmonary endothelial cell barrier enhancement. Cell Signal. 2011;23(12):2086–96.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Adyshev DM, Dudek SM, Moldobaeva N, Kim KM, Ma SF, Kasa A, Garcia JG, Verin AD. Ezrin/radixin/moesin proteins differentially regulate endothelial hyperpermeability after thrombin. Am J Physiol Lung Cell Mol Physiol. 2013;305(3):L240–55.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Canals D, Roddy P, Hannun YA. Protein phosphatase 1alpha mediates ceramide-induced ERM protein dephosphorylation: a novel mechanism independent of phosphatidylinositol 4, 5-biphosphate (PIP2) and myosin/ERM phosphatase. J Biol Chem. 2012;287(13):10145–55.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Forte E, Orsatti L, Talamo F, Barbato G, De Francesco R, Tomei L. Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3. Biochim Biophys Acta. 2008;1783(2):334–44.

    CAS  Article  PubMed  Google Scholar 

  40. 40.

    Fukata Y, Kimura K, Oshiro N, Saya H, Matsuura Y, Kaibuchi K. Association of the myosin-binding subunit of myosin phosphatase and moesin: dual regulation of moesin phosphorylation by Rho-associated kinase and myosin phosphatase. J Cell Biol. 1998;141(2):409–18.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Shcherbina A, Bretscher A, Kenney DM, Remold-O’Donnell E. Moesin, the major ERM protein of lymphocytes and platelets, differs from ezrin in its insensitivity to calpain. FEBS Lett. 1999;443(1):31–6.

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Wang Z, Schey KL. Aquaporin-0 interacts with the FERM domain of ezrin/radixin/moesin proteins in the ocular lens. Invest Ophthalmol Vis Sci. 2011;52(8):5079–87.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, Tsukita S. Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol. 1998;140(4):885–95.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Weinman EJ, Hall RA, Friedman PA, Liu-Chen LY, Shenolikar S. The association of NHERF adaptor proteins with g protein-coupled receptors and receptor tyrosine kinases. Annu Rev Physiol. 2006;68:491–505.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Reczek D, Berryman M, Bretscher A. Identification of EBP50: A PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family. J Cell Biol. 1997;139(1):169–79.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Chirivino D, Del Maestro L, Formstecher E, Hupe P, Raposo G, Louvard D, Arpin M. The ERM proteins interact with the HOPS complex to regulate the maturation of endosomes. Mol Biol Cell. 2011;22(3):375–85.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Granes F, Urena JM, Rocamora N, Vilaro S. Ezrin links syndecan-2 to the cytoskeleton. J Cell Sci. 2000;113(Pt 7):1267–76.

    CAS  PubMed  Google Scholar 

  48. 48.

    Parlato S, Giammarioli AM, Logozzi M, Lozupone F, Matarrese P, Luciani F, Falchi M, Malorni W, Fais S. CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 2000;19(19):5123–34.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Sarrio D, Rodriguez-Pinilla SM, Dotor A, Calero F, Hardisson D, Palacios J. Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat. 2006;98(1):71–9.

    CAS  Article  PubMed  Google Scholar 

  50. 50.

    Naba A, Reverdy C, Louvard D, Arpin M. Spatial recruitment and activation of the Fes kinase by ezrin promotes HGF-induced cell scattering. EMBO J. 2008;27(1):38–50.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Ng T, Parsons M, Hughes WE, Monypenny J, Zicha D, Gautreau A, Arpin M, Gschmeissner S, Verveer PJ, Bastiaens PI, et al. Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J. 2001;20(11):2723–41.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  52. 52.

    Legg JW, Lewis CA, Parsons M, Ng T, Isacke CM. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat Cell Biol. 2002;4(6):399–407.

    CAS  Article  PubMed  Google Scholar 

  53. 53.

    Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze’ev A. Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci. 2010;123(Pt 12):2135–43.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Konstantinovsky S, Davidson B, Reich R. Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids. Clin Exp Metastasis. 2012;29(6):527–40.

    CAS  Article  PubMed  Google Scholar 

  55. 55.

    Elliott BE, Qiao H, Louvard D, Arpin M. Co-operative effect of c-Src and ezrin in deregulation of cell-cell contacts and scattering of mammary carcinoma cells. J Cell Biochem. 2004;92(1):16–28.

    CAS  Article  PubMed  Google Scholar 

  56. 56.

    Srivastava J, Elliott BE, Louvard D, Arpin M. Src-dependent ezrin phosphorylation in adhesion-mediated signaling. Mol Biol Cell. 2005;16(3):1481–90.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Li Q, Gao H, Xu H, Wang X, Pan Y, Hao F, Qiu X, Stoecker M, Wang E. Expression of ezrin correlates with malignant phenotype of lung cancer, and in vitro knockdown of ezrin reverses the aggressive biological behavior of lung cancer cells. Tumour Biol. 2012;33(5):1493–504.

    CAS  Article  PubMed  Google Scholar 

  58. 58.

    Valdman A, Fang X, Pang ST, Nilsson B, Ekman P, Egevad L. Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol. 2005;48(5):852–7.

    CAS  Article  PubMed  Google Scholar 

  59. 59.

    Pang ST, Fang X, Valdman A, Norstedt G, Pousette A, Egevad L, Ekman P. Expression of ezrin in prostatic intraepithelial neoplasia. Urology. 2004;63(3):609–12.

    Article  PubMed  Google Scholar 

  60. 60.

    Chuan YC, Iglesias-Gato D, Fernandez-Perez L, Cedazo-Minguez A, Pang ST, Norstedt G, Pousette A, Flores-Morales A. Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene. 2010;29(10):1531–42.

    CAS  Article  PubMed  Google Scholar 

  61. 61.

    Clucas J, Valderrama F. ERM proteins in cancer progression. J Cell Sci. 2015;128(6):1253.

    CAS  Article  PubMed  Google Scholar 

  62. 62.

    Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med. 2004;10(5):201–4.

    CAS  Article  PubMed  Google Scholar 

  63. 63.

    Meng Y, Lu Z, Yu S, Zhang Q, Ma Y, Chen J. Ezrin promotes invasion and metastasis of pancreatic cancer cells. J Transl Med. 2010;8:61.

    Article  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Shang X, Wang Y, Zhao Q, Wu K, Li X, Ji X, He R, Zhang W. siRNAs target sites selection of ezrin and the influence of RNA interference on ezrin expression and biological characters of osteosarcoma cells. Mol Cell Biochem. 2012;364(1-2):363–71.

    CAS  Article  PubMed  Google Scholar 

  65. 65.

    Bartholow TL, Chandran UR, Becich MJ, Parwani AV. Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma. BMC Clin Pathol. 2011;11:1.

    Article  PubMed  PubMed Central  Google Scholar 

  66. 66.

    Chen SD, Song MM, Zhong ZQ, Li N, Wang PL, Cheng S, Bai RX, Yuan HS. Knockdown of radixin by RNA interference suppresses the growth of human pancreatic cancer cells in vitro and in vivo. Asian Pac J Cancer Prev. 2012;13(3):753–9.

    Article  PubMed  Google Scholar 

  67. 67.

    Abe K, Rossman KL, Liu B, Ritola KD, Chiang D, Campbell SL, Burridge K, Der CJ. Vav2 is an activator of Cdc42, Rac1, and RhoA. J Biol Chem. 2000;275(14):10141–9.

    CAS  Article  PubMed  Google Scholar 

  68. 68.

    Louvet-Vallee S. ERM proteins: from cellular architecture to cell signaling. Biol Cell. 2000;92(5):305–16.

    CAS  Article  PubMed  Google Scholar 

  69. 69.

    Kahsai AW, Zhu S, Fenteany G. G protein-coupled receptor kinase 2 activates radixin, regulating membrane protrusion and motility in epithelial cells. Biochim Biophys Acta. 2010;1803(2):300–10.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Valderrama F, Thevapala S, Ridley AJ. Radixin regulates cell migration and cell-cell adhesion through Rac1. J Cell Sci. 2012;125(Pt 14):3310–9.

    CAS  Article  PubMed  Google Scholar 

  71. 71.

    Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, Kurashina K, Taniguchi S. Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res. 2004;10(2):572–80.

    CAS  Article  PubMed  Google Scholar 

  72. 72.

    Zhu X, Morales FC, Agarwal NK, Dogruluk T, Gagea M, Georgescu MM. Moesin is a glioma progression marker that induces proliferation and Wnt/beta-catenin pathway activation via interaction with CD44. Cancer Res. 2013;73(3):1142–55.

    CAS  Article  PubMed  Google Scholar 

  73. 73.

    Estecha A, Sanchez-Martin L, Puig-Kroger A, Bartolome RA, Teixido J, Samaniego R, Sanchez-Mateos P. Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci. 2009;122(Pt 19):3492–501.

    CAS  Article  PubMed  Google Scholar 

  74. 74.

    Haynes J, Srivastava J, Madson N, Wittmann T, Barber DL. Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol Biol Cell. 2011;22(24):4750–64.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  75. 75.

    Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, Cervera N, Geneix J, Hassanein M, Rabayrol L, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer. 2007;121(8):1779–85.

    CAS  Article  PubMed  Google Scholar 

  76. 76.

    Condeelis J, Singer RH, Segall JE. The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol. 2005;21:695–718.

    CAS  Article  PubMed  Google Scholar 

  77. 77.

    Abiatari I, Esposito I, Oliveira TD, Felix K, Xin H, Penzel R, Giese T, Friess H, Kleeff J. Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer. J Cell Mol Med. 2010;14(5):1166–79.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. 78.

    Wang CC, Liau JY, Lu YS, Chen JW, Yao YT, Lien HC. Differential expression of moesin in breast cancers and its implication in epithelial-mesenchymal transition. Histopathology. 2012;61(1):78–87.

    Article  PubMed  Google Scholar 

  79. 79.

    Belbin TJ, Singh B, Smith RV, Socci ND, Wreesmann VB, Sanchez-Carbayo M, Masterson J, Patel S, Cordon-Cardo C, Prystowsky MB, et al. Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2005;131(1):10–8.

    Article  PubMed  Google Scholar 

  80. 80.

    Cui Y, Wu J, Zong M, Song G, Jia Q, Jiang J, Han J. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer. 2009;124(7):1614–21.

    CAS  Article  PubMed  Google Scholar 

Download references


Special thanks to Dr. Phil Dash at the Cell migration laboratory, University of Reading, United Kingdom for editing the work.

Author information



Corresponding author

Correspondence to Godwin A. Ponuwei.

Additional information

Competing interests

The author declare that there are no competing interests.

Authors’ contribution

GAP conceptualized and wrote the manuscript.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ponuwei, G.A. A glimpse of the ERM proteins. J Biomed Sci 23, 35 (2016).

Download citation


  • Ezrin
  • Radixin
  • Moesin
  • Plasma membrane
  • Phospholipids
  • Cancer